Vero Beach, FL (FSCwire) - Nascent Biotech, Inc. (OTC: NBIO) has engaged HRA
Capital to assist the Company in raising the necessary capital to fund the continual development of Nascent’s primary asset,
Pritumumab through its phase I and II clinical trials.
Nascent CEO, Sean Carrick stated, “We are excited with this new partnership and while we have been very successful
raising funds internally, Nascent has reached an inflection point which will require a larger raise requiring capital market
expertise.”
The President of HRA Capital, Ted Kalem states “We welcome the opportunity to assist Nascent in advancing its asset
by raising the necessary funds so Nascent can proceed with its clinical trials.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be
used in the treatment of various cancers. Its products are not commercially available. For further information please visit
our website www.nascentbiotech.com.
About HRA Capital:
HRA Capital is an institutional investment banking group providing premium services to leading companies in the
healthcare sector. It offers the full spectrum of investment banking services, including financings, M&A and advisory
services to clients across the full range of market capitalizations, from start-ups to Big Pharma companies.
Safe Harbor:
Statements in this press release about our future expectations constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is
defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and
are subject to change at any time, and our actual results could differ materially from expected results. These risks and
uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech
Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be
described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange
Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to
reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as
required by law.
Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President |CEO
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/Nascent08092017.pdf
Source: Nascent Biotech Inc. (OTC Pink:NBIO)
To follow Nascent Biotech Inc. on your favorite social media platform or financial websites, please click on the icons
below.
Maximum News Dissemination by FSCwire. http://www.fscwire.com
Copyright © 2017 Filing Services Canada Inc.